On 11 November and 9 December 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency published updated safety information on COVID-19 vaccines. The spontaneously reported cases concern adverse events observed after vaccination but not necessarily related to it.
Spikevax and Comirnaty
Myocarditis and pericarditis
Update of the instructions for medical use
PRAC assessed the latest data on the known risk of myocarditis and pericarditis after vaccination with mRNA vaccines, including Spikevax and Comirnaty. This review included two large European epidemiological studies.
The results of the review confirm the risk of myocarditis and pericarditis, which is already reflected in the instructions for medical use for Spikevax and Comirnaty, and provide additional information on these two conditions.
Based on the data reviewed, PRAC determined the frequency of the specified conditions as “very rare”. In addition, the data indicate that the risk of myocarditis after vaccination is highest in young men. PRAC recommends updating the instructions for medical use accordingly.
The European Medicines Agency (EMA) confirms that the benefits of the Spikevax and Comirnaty vaccines continue to outweigh the risks.
Multisystem inflammatory syndrome
Assessment ongoing
The PRAC concluded that there is currently insufficient evidence of a possible link between the use of Spikevax and Comirnaty vaccines and very rare cases of multisystem inflammatory syndrome.
The assessment is based on spontaneous report data and currently does not require an update of the instructions for medical use. Most reports lacked sufficient information to establish a causal relationship.
Autoimmune hepatitis
Signal evaluation has been started
The PRAC has started an evaluation of cases of autoimmune hepatitis to establish whether it may be an adverse reaction to the use of Spikevax and Comirnaty vaccines.
The assessment is based on a very small number of reports, therefore PRAC requested additional data from marketing authorization holders.
Spikevax
Capillary leak syndrome (CLS)
Signal evaluation has been started
PRAC has begun evaluating a signal regarding capillary leak syndrome (CLS) in people vaccinated with Spikevax.
Six cases of this very rare condition were reported in the EudraVigilance database. At this stage it is not yet clear whether there is a causal relationship between vaccination and the reports of CLS.
Vaxzevria
Thrombosis of cerebral veins and sinuses
Update of the instructions for medical use
PRAC completed its evaluation of cases in which cerebral venous and sinus thrombosis without thrombocytopenia was reported after vaccination with Vaxzevria. Thrombosis with thrombocytopenia syndrome is already a known very rare adverse reaction of Vaxzevria.
The PRAC evaluated all available data and recommended updating the instructions for medical use and adding cerebral venous and sinus thrombosis to the “Adverse reactions” section with the frequency “Not known”
Vaxzevria and Janssen
Multisystem inflammatory syndrome
PRAC concluded that at present there is insufficient evidence of a possible association between the use of the Vaxzevria and Janssen vaccines and very rare cases of multisystem inflammatory syndrome.
Janssen
Small vessel vasculitis of the skin
Update of the instructions for medical use
PRAC recommends adding cutaneous small vessel vasculitis to the “Adverse reactions” section of the instructions for medical use with the frequency “Not known”.
EMA confirms that the benefit of the Janssen COVID-19 vaccine continues to outweigh the risks, taking into account the risk of COVID-19 and its associated complications, including hospitalization and death.
Menstrual cycle disorders
The PRAC concluded that there is insufficient evidence to establish a causal relationship between the use of the Janssen COVID-19 vaccine and menstrual cycle disorders.
The evaluation of all spontaneously reported cases included an analysis of the type of symptoms, their time of onset and duration, as well as concomitant treatment and medical history/current conditions; however, the nature of the menstrual cycle disorders has not yet been established.
The original text of the publication can be found at the links: